Why the study?
HCV genetic diversity and quasispecies cause resistance to direct-acting antivirals and impede vaccine development, prompting exploration of CRISPR-Cas as an alternative antiviral strategy.
Population
huh-7.5 cells
Comparison
Cas13a targeting conserved regions of the HCV IRES
Design
In vitro experimental study
Authors
Loading...
May enable targeted HCV RNA degradation; leaves open clinical translation against resistant strains.
CRISPR-Cas13a efficiently targets HCV in vitro, suggesting its potential as a programmable therapeutic antiviral strategy.
Ashraf et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: